Gilead Sciences (GILD) Construction in Progress (2010 - 2025)
Gilead Sciences' (GILD) quarterly Construction in Progress came in at $745.0 million in Q4 2025, up 48.7% on a YoY basis from $501.0 million in Q4 2024, and up 48.7% quarter-over-quarter from $501.0 million in Q4 2024.
Analysis
Gilead Sciences (GILD) Construction in Progress (2010 - 2025) Analysis & Trends
Gilead Sciences (GILD) has reported Construction in Progress for 16 consecutive years, with $745.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Construction in Progress rose 48.7% year-over-year to $745.0 million; the trailing twelve-month figure through Dec 2025 stood at $745.0 million (up 48.7% YoY), and the FY2025 full-year result was $745.0 million, up 48.7% from the prior year.
- Construction in Progress improved to $745.0 million in Q4 2025 per GILD's latest filing, from $501.0 million in the prior quarter.
- Across five years, Construction in Progress topped out at $1.1 billion in Q4 2021 and bottomed at $501.0 million in Q4 2024.
- Historically, Construction in Progress has averaged $736.6 million across 5 years, with a median of $719.0 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Construction in Progress plunged 31.98% in 2022, then surged 48.7% in 2025.
- Over 5 years, Construction in Progress stood at $1.1 billion in 2021, then slumped by 31.98% to $719.0 million in 2022, then slipped by 8.07% to $661.0 million in 2023, then slipped by 24.21% to $501.0 million in 2024, then soared by 48.7% to $745.0 million in 2025.
- According to Business Quant data, Construction in Progress over the past three periods registered $745.0 million, $501.0 million, and $661.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 745.00 Mn |
| Dec 31, 2024 | 501.00 Mn |
| Dec 31, 2023 | 661.00 Mn |
| Dec 31, 2022 | 719.00 Mn |
| Dec 31, 2021 | 1.06 Bn |
| Dec 31, 2020 | 856.00 Mn |
| Dec 31, 2019 | 723.00 Mn |
| Dec 31, 2018 | 1.19 Bn |
| Dec 31, 2017 | 690.00 Mn |
| Dec 31, 2016 | 641.00 Mn |
| Dec 31, 2015 | 554.00 Mn |
| Dec 31, 2014 | 411.00 Mn |
| Dec 31, 2013 | 129.00 Mn |
| Dec 31, 2012 | 216.43 Mn |
| Dec 31, 2011 | 60.75 Mn |
| Dec 31, 2010 | 82.33 Mn |